These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 7741141

  • 1. Recombinant hirudin (HBW 023): biological data of ten patients with severe venous thrombo-embolism.
    Bridey F, Dreyfus M, Parent F, Bros A, Fischer AM, Camez A, Simonneau G, Duroux P, Meyer D.
    Am J Hematol; 1995 May; 49(1):67-72. PubMed ID: 7741141
    [Abstract] [Full Text] [Related]

  • 2. Treatment of severe venous thrombo-embolism with intravenous Hirudin (HBW 023): an open pilot study.
    Parent F, Bridey F, Dreyfus M, Musset D, Grimon G, Duroux P, Meyer D, Simonneau G.
    Thromb Haemost; 1993 Sep 01; 70(3):386-8. PubMed ID: 8259534
    [Abstract] [Full Text] [Related]

  • 3. Recombinant hirudin as a periprocedural antithrombotic in coronary angioplasty for unstable angina pectoris.
    Hafner G, Rupprecht HJ, Luz M, Terres W, Schindel F, Friesen HJ, Heinrichs H, Jessel A, Meyer J, Prellwitz W.
    Eur Heart J; 1996 Aug 01; 17(8):1207-15. PubMed ID: 8869862
    [Abstract] [Full Text] [Related]

  • 4. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes.
    Flather MD, Weitz JI, Yusuf S, Pogue J, Sussex B, Campeau J, Gill J, Schuld R, Joyner CD, Morris AL, Lai C, Théroux P, Marquis JF, Chan YK, Venkatesh G, Jessel A.
    Eur Heart J; 2000 Sep 01; 21(17):1473-81. PubMed ID: 10952840
    [Abstract] [Full Text] [Related]

  • 5. Distinct effects of recombinant desulfatohirudin (Revasc) and heparin on plasma levels of fibrinopeptide A and prothrombin fragment F1.2 in unstable angina. A multicenter trial.
    Rao AK, Sun L, Chesebro JH, Fuster V, Harrington RA, Schwartz D, Gallo P, Matos D, Topol EJ.
    Circulation; 1996 Nov 15; 94(10):2389-95. PubMed ID: 8921778
    [Abstract] [Full Text] [Related]

  • 6. A pilot study of subcutaneous recombinant hirudin (HBW 023) in the treatment of deep vein thrombosis.
    Schiele F, Vuillemenot A, Kramarz P, Kieffer Y, Soria J, Soria C, Camez A, Mirshahi MC, Bassand JP.
    Thromb Haemost; 1994 May 15; 71(5):558-62. PubMed ID: 8091380
    [Abstract] [Full Text] [Related]

  • 7. Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. European Hirudin in Thrombosis Group.
    Verstraete M, Nurmohamed M, Kienast J, Siebeck M, Silling-Engelhardt G, Büller H, Hoet B, Bichler J, Close P.
    J Am Coll Cardiol; 1993 Oct 15; 22(4):1080-8. PubMed ID: 8409044
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Persistent thrombin generation in humans during specific thrombin inhibition with hirudin.
    Zoldhelyi P, Bichler J, Owen WG, Grill DE, Fuster V, Mruk JS, Chesebro JH.
    Circulation; 1994 Dec 15; 90(6):2671-8. PubMed ID: 7994807
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Influence of recombinant hirudin on tissue-factor-induced activation of coagulation in rabbits.
    Kouz J, Czech J, Nicolay U, Dickneite G.
    Haemostasis; 1996 Dec 15; 26(4):179-86. PubMed ID: 8872128
    [Abstract] [Full Text] [Related]

  • 13. Laboratory assays for the evaluation of recombinant hirudin.
    Walenga JM, Hoppensteadt D, Koza M, Wallock M, Pifarre R, Fareed J.
    Haemostasis; 1991 Dec 15; 21 Suppl 1():49-63. PubMed ID: 1894197
    [Abstract] [Full Text] [Related]

  • 14. Pharmacodynamic and safety results of PEG-Hirudin in healthy volunteers.
    Esslinger HU, Haas S, Maurer R, Lassmann A, Dübbers K, Müller-Peltzer H.
    Thromb Haemost; 1997 May 15; 77(5):911-9. PubMed ID: 9184402
    [Abstract] [Full Text] [Related]

  • 15. Recombinant hirudin (HBW 023) produces stable anticoagulation unaffected by circadian variation in patients with thrombolysis for acute myocardial infarction.
    Zeymer U, Mateblowski M, Neuhaus KL.
    Eur Heart J; 1996 Dec 15; 17(12):1836-40. PubMed ID: 8960425
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Clinical pharmacology of recombinant hirudin.
    Markwardt F, Nowak G, Stürzebecher J.
    Haemostasis; 1991 Dec 15; 21 Suppl 1():133-6. PubMed ID: 1894188
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.